EMA issues procedural advice on CAT-NB interaction for combination ATMPs
This article was originally published in SRA
Executive Summary
The European Medicines Agency has finalised its much-awaited procedural advice on how its Committee for Advanced Therapies should interact with notified bodies when assessing advanced therapy medicinal products that incorporate medical devices (ie combination ATMPs)1.